Why phesi
Phesi has been at the table with life sciences companies guiding clinical development since our inception in 2007.
INNOVATIVE
We build clinical development solutions using patented statistical models and advanced technologies such as big data, nature language processing, and machine learning.
FLEXIBLE
We provide fully customized services to clinical trial sponsors or CROs of any size, and ensure easy integration with their existing solutions.
COMPREHENSIVE
Our massive database provides insights to clinical studies of all phases across all therapeutic areas from all countries and geographical regions.
EFFECTIVE
Proven by hundreds of clinical studies, our solutions help our clients improve clinical operation productivity, saving them a huge amount of time and money.
CLIENT Testimonials
Phesi worked with us to show that a particular adaptive trial design would give the best performance. The result was a significantly quicker and cheaper development time on this priority asset.
Phesi is on the frontiers of defining clinical development as a science, performing systematic analysis of the clinical trial, clinical protocol, and clinical site space to form hypotheses about what will work and what will not. Through observation and experiment you are applying those learnings to inform new clinical programs or save old ones. Phesi is more than the sum of its parts and the value is in the integration.
Every global R&D leader should know about this and should be testing it within their portfolio.
LATEST NEWS
East Lyme, Connecticut, USA: Analysis from Phesi shows the impact of COVID-19 on clinical development is continuing to mount, with many clinical trial sites unable to bounce back following suspension in March and April 2020
East Lyme, Connecticut, USA: Phesi, a data-driven provider of clinical development analytics products and solutions, today announced a new country selection functionality has been added to ClinSite, its platform to provide investigator site intelligence to clients, enabling investigator site selection and management. The new functionality has been added in response to the industry-wide problem of non-performing countries and sites being…
EAST LYME, Conn. Phesi, a data-driven provider of premier integrated clinical development analytics products and services, today announced that OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS) has purchased a multi-year ClinSite™ license to enable more accurate and precise planning for Phase 2 and 3 clinical trials of anticancer immunotherapies developed with OncoSec’s plasmid DNA delivery platform. ClinSite is a self-service, artificial intelligence (AI)-powered…